Oliveras-Ferraros et al. described FGFR3 hyperactivation in cetuximab-resistant epidermoid carcinoma cells and identified a synergistic effect in the combination of cetuximab plus an FGFR3 inhibitor in these cells26. The gene discussed is FGFR3; the disease is squamous cell carcinoma.